**Comorbidities of migraine**

**Shuu-Jiun Wang 1,2*, Ping-Kun Chen 3,4 and Jong-Ling Fuh 1,2**

1 Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan  
2 National Yang-Ming University School of Medicine, Taipei, Taiwan  
3 Department of Neurology, Lin-Shin Hospital, Taichung, Taiwan  
4 Graduate Institute of Clinical Medicine Science, China Medical University, Taichung, Taiwan

**Edited by:**  
Mario Peres, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Brazil  
**Reviewed by:**  
Giancarlo Lucchetti, Centro de Terapia Intensiva, Hospital de Aeronáutica de São Paulo, Brazil  
Marcelo Valença, Federal University of Pernambuco, Brazil  
*Correspondence:*  
Shuu-Jiun Wang, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei 112, Taiwan.  
e-mail: sjwang@vghtpe.gov.tw

**INTRODUCTION**

Migraine is one of the most common neurological disorders (Andlin-Sobocki et al., 2005). It causes substantial levels of disability; however, the burden of migraine is underestimated in scope and scale. In most countries, migraine is under-recognized and under-treated (Stewart et al., 1992; Wang et al., 2000).

The term comorbidity is used to refer to the statistical association of two distinct diseases in the same individual at a rate higher than expected by chance (Lipton and Silberstein, 1994). Many illnesses are reported to be comorbid with migraine (Scher et al., 2005a), which stresses the clinical complexity of this headache disorder. Comorbidity in migraine is important from several perspectives: (1) co-occurrence of diseases can complicate the diagnosis, e.g., focal sign of migraine and stroke; (2) one disease can remind the clinicians of the other diseases, e.g., migraine and restless legs syndrome (RLS); (3) one treatment for two diseases, e.g., tricyclic antidepressants for migraine patients with depressive disorders; and (4) comorbidity of illnesses can provide clues to the pathophysiology of migraine.

This review focuses on the findings of common comorbid disorders of migraine, which include stroke, sub-clinical vascular brain lesions, coronary heart disease, hypertension, patent foramen ovale (PFO), psychiatric diseases, RLS, obesity, epilepsy, asthma and other disorders.

**COMORBIDITY OF MIGRAINE**

**CARDIOVASCULAR DISORDERS (CVD)**

The vascular component of CVD is suspected to be part of the pathophysiology of migraine and led to the therapeutic development of triptans. Many studies delineate the association between migraine and vascular problems. In this section, we focus on the relationship between migraine and stroke, sub-clinical vascular brain lesions, coronary artery disease, hypertension and PFO. Table 1 summarizes the studies of CVD and migraine.

**Keywords:** migraine, cerebrovascular disorder, depression, anxiety, comorbidity

**Table 1**

| Illnesses | References |
|-----------|------------|
| Stroke    | Andlin-Sobocki et al., 2005 |
| Ischemic stroke | Stang et al., 2005 |
| Transient ischemic attack (TIA) | Stang et al., 2005 |

**Stroke**

The association between migraine and ischemic stroke has been well known from many case-control and cohort studies. The Atherosclerosis Risk in Communities Study in the United States (Stang et al., 2005) recorded the lifetime headache history of participants by using the modified International Headache Society (IHS) diagnostic criteria, and the stroke events were identified and validated using medical records. The results showed migraine with aura was associated with stroke symptoms [odds ratio (OR) 5.46], transient ischemic attack (TIA) symptoms (OR 4.28), and verified ischemic stroke events (OR 2.81). Another important piece of evidence came from a prospective analysis on the risk of ischemic stroke in the Women's Health Study (Kurth et al., 2005). Nearly 40,000 healthy females aged 45 years and older, and without a history of stroke, TIA or an abnormal neurological examination, were followed up for a mean of 9 years. Migraine and aura were based on self-report. In this prospective study, migraine with aura was associated with incidents of ischemic stroke [Hazard ratio (HR) 1.70], with the risks most evident for those under 55 years of age at baseline (HR 2.25). In the subgroup of Women's Health Study (Kurth et al., 2006), after adjustment of the risk factors for major CVD including age, blood pressure, antihypertensive medication, diabetes, body mass index (BMI), smoking, alcohol consumption, menstrual status, hormone levels, oral contraceptive use and cholesterol, active migraine with aura was associated with an increased risk of ischemic stroke. Importantly, women who reported active migraine without aura were not significantly related to an increased risk...
Table 1 | Summary of the studies of cardiovascular disorders (CVD) and migraine.

| Study                                              | Population          | N          | Results                                                                 |
|----------------------------------------------------|---------------------|------------|-------------------------------------------------------------------------|
| **ISCHEMIC STROKE AND TRANSIENT ISCHEMIC ATTACK (TIA)** |                     |            |                                                                         |
| Atherosclerosis Risk in Communities Study (Stang et al., 2005) | Both sexes (45–64)  | 12,750     | An association with stroke symptoms, TIA symptoms, and verified ischemic stroke events | Increased risk of stroke symptoms |
| Women's Health Study (Kurth et al., 2005)          | Women (≥45)         | 39,717     | An association with ischemic stroke                                    | No association with ischemic stroke |
| Women's Health Study (Kurth et al., 2006)          | Women (≥45)         | 27,840     | An association with ischemic stroke                                    | No association with ischemic stroke |
| Women's Health Study (Kurth et al., 2008)          | Women (≥45)         | 27,519     | An association with ischemic stroke only in the low Framingham risk score group | No association with ischemic stroke in any of the Framingham risk score groups |
| Physicians' Health Study (Kurth et al., 2007)      | Men (40–84)         | 20,084     | The age-adjusted HR of ischemic stroke was increased in men with migraine younger than 55 years |                                                                         |
| American Migraine Prevalence and Prevention (AMPP) study (Bigal et al., 2010) | Both sexes (≥45) | 11,345 (6102 migraine and 5243 controls) | An association with CVD and risk factors for CVD | An association with CVD and of risk factors for CVD |
| **SUB-CLINICAL CEREBRAL LESIONS**                   |                     |            |                                                                         |
| Cerebral Abnormalities in Migraine, an Epidemiological Risk Analysis (CAMERA) study (Kruit et al., 2004) | Both sexes (30–60) | 161 migraine with aura, 134 migraine without aura, 140 controls | An association with the posterior circulation territory infarcts | No association with the posterior circulation infarcts |
| AGES-Reykjavik Study (Scher et al., 2009)          | Both sexes (33–65)  | 4,689      | An association with cerebellar infarct-like lesions in women, but not men | No association with cerebellar infarct-like lesions |
| **CORONARY HEART DISEASE**                         |                     |            |                                                                         |
| Atherosclerosis Risk in Communities Study (Rose et al., 2004) | Both sexes (45–64)  | 12,409     | Rose angina was more frequent in migraine patients, and the associations were stronger for migraine with aura. The risk of coronary heart disease did not increase in migraine patients |                                                                         |
| Women's Health Study (Kurth et al., 2006)          | Women (≥45)         | 27,840     | An association with myocardial infarction, angina, and coronary revascularization | No association with myocardial infarction, angina, and coronary revascularization |
| Physicians' Health Study (Kurth et al., 2007)      | Men (40–84)         | 20,084     | Men with migraine were driven by 42% increase in the risk of myocardial infarction, and 24% increased risk for major CVD after adjusted cardiovascular risk factors |                                                                         |
| American Migraine Prevalence and Prevention (AMPP) study (Bigal et al., 2010) | Both sexes (≥45) | 11,345 (6102 migraine and 5243 controls) | An association with myocardial infarction | An association with myocardial infarction |

risk of ischemic stroke in this study. Furthermore, a recent report from the same group also showed the association between ischemic stroke and active migraine with aura in women only in the low Framingham risk score group (10-year risk of coronary heart disease < 1%, HR: 3.88; 95% CI, 1.87–8.08) (Kurth et al., 2008). In consideration of the individual components of the Framingham risk score, this diatomic pattern of association was driven by a particularly increased risk of ischemic stroke among women with active migraine with aura who were young (aged 45–49) and had low total cholesterol concentrations. With regard to men, prospective
data from the Physicians’ Health Study investigated the association between migraine and CVD in men (Kurth et al., 2007). In this study, 20,084 apparently healthy US male physicians aged 40–84 at study entry were followed for a mean of 15.7 years. The age-adjusted HR of ischemic stroke was increased in men with migraine younger than 55 years [relative risk (RR): 1.84; 95% CI: 1.10–3.08]. This association was not found in older age groups. One recent population-based study [part of the American Migraine Prevalence and Prevention (AMPP) study] found a positive association between migraine with aura and stroke in both adult men and women (Bigal et al., 2010). After adjustment for age, gender, disability, treatment and CVD risk factors, migraine with aura remained significantly associated with stroke (Bigal et al., 2010).

**Sub-clinical vascular brain lesions**

Sub-clinical cerebral lesions, especially in the posterior circulation or white matter, were reported to be more frequent in patients with migraine (especially migraine with aura) in a case-controlled MRI study (CAMERA) (Kruit et al., 2004). The same group also demonstrated that most (88%) infratentorial infarct-like lesions had a vascular border zone location in the cerebellum and, further, that a combination of hypoperfusion (possibly migraine attack-related) and embolism is the most likely mechanism for posterior circulation infarction in migraine (Kruit et al., 2005). Recently, MRI was performed in participants of the AGES-Reykjavik Study, more than 26 years after the initial headache diagnosis. Women, but not men, with migraine with aura in midlife were associated with increased cerebellar infarct-like lesions in late life (Sché et al., 2009).

**Coronary heart disease**

The association between migraine and coronary artery disease was conflicting in several large-scale population-based studies. Of 12,409 participants, the Atherosclerosis Risk in Communities Study evaluated the prevalence of Rose angina and coronary artery disease (Rose et al., 2004). After more than 10 years of follow-up, Rose angina was more frequent in migraine patients, and the associations were stronger for migraine with aura [prevalence ratio (PR):3.0, 95% CI: 2.4–3.7]. Nevertheless, the risk of coronary heart disease did not increase in migraineurs with aura (RR = 0.79; 95% CI, 0.65–0.96; p = 0.02), but was not associated with ischemic stroke or myocardial infarction. However, co-existence of migraine with aura and the 677TT genotype further increases the risk for major CVD (HR = 3.66; 95% CI = 1.69–7.90; p = 0.001). This pattern was only apparent in ischemic stroke (HR = 4.19; 95% CI = 1.38–12.74; p = 0.01), but not in myocardial infarction (HR = 2.88; 95% CI = 0.84–9.88; p = 0.09). The ACE D/I polymorphism was studied in the same cohort (Schürks et al., 2009). There is no association between the ACE D/I polymorphism, and migraine or CVD. However, the risk of CVD was doubled in migraine with aura patients, but only for carriers of the DD/DI genotype. The risk was not increased among carriers of the II genotype. Due to the limited number of outcome events, future studies are warranted to further investigate this association.

**Hypertension and other CVD risk factor**

Reports on the relationship between migraine and hypertension are controversial. The positive association was noted in two clinic-based studies (Franceschi et al., 1997; Cirillo et al., 1999), and no association in one population-based study (Rasmussen and Olesen, 1992). Actually, two prospective population-based studies demonstrated a negative association between migraine and hypertension (Wiehe et al., 2002; Tzourio et al., 2003). The CVD risk factors were recorded in several population-based studies to evaluate the associations between migraine, and stroke or coronary artery disease. The GEM study (Scher et al., 2005b) and AMPP sub-study (Bigal et al., 2010) demonstrated a higher cardiovascular risk profile in migraineurs with higher cholesterol and blood pressure levels. However, this result was not confirmed in the Women’s Health Study (Kurth et al., 2006). Further studies are needed to confirm the relationship between blood pressure and other CVD risk factors in migraine patients.

**Gene polymorphisms**

Two important gene polymorphisms were studied in both migraine and CVD: the 677C>T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene, and the D/I polymorphism of the angiotensin-converting enzyme (ACE) gene. The MTHFR 677C>T polymorphism was investigated in the Women’s Health Study (Schürks et al., 2008). The study found that the 677TT genotype was associated with a 20% reduced risk for migraine with aura (RR = 0.79; 95% CI, 0.65–0.96; p = 0.02), but was not associated with ischemic stroke or myocardial infarction. However, co-existence of migraine with aura and the 677TT genotype further increases the risk for major CVD (HR = 3.66; 95% CI = 1.69–7.90; p = 0.001). This pattern was only apparent in ischemic stroke (HR = 4.19; 95% CI = 1.38–12.74; p = 0.01), but not in myocardial infarction (HR = 2.88; 95% CI = 0.84–9.88; p = 0.09). The ACE D/I polymorphism was studied in the same cohort (Schürks et al., 2009). There is no association between the ACE D/I polymorphism, and migraine or CVD. However, the risk of CVD was doubled in migraine with aura patients, but only for carriers of the DD/DI genotype. The risk was not increased among carriers of the II genotype. Due to the limited number of outcome events, future studies are warranted to further investigate this association.

**Patent foramen ovale (PFO)**

An association between PFO and migraine has been identified in many studies (Del Sette et al., 1998; Anzola et al., 1999; Ferrarini et al., 2005; Schwerzmann et al., 2005; Carod-Aralt et al., 2006). It is hypothesized that right-to-left shunts via PFO may allow for paradoxical embolism, and passage of higher concentrations of vasoactive substances into the cerebral arterial system (Buzzi and Moskowitz, 2005; Schwedt and Dodick, 2006). In most studies, PFO is common in patients with migraine with aura (Del Sette et al., 1998; Anzola et al., 1999; Ferrarini et al., 2005; Schwerzmann et al., 2005), and some retrospective studies suggest that PFO closure is effective for migraine treatment (Post et al., 2004; Schwerzmann et al., 2004). However, several studies reported different results: in a cross-sectional study from the Northern Manhattan Study (NOMAS), 1101 stroke-free precipitants aged > 39-years old (mean 69±10-years old) were
examined by transthoracic echocardiography for PFO. There was no difference in the prevalence of PFO between participants with and without migraine (Rundek et al., 2008). In the Migraine Intervention with STARFlex Technology (MIST) trial – a prospective, randomized, double-blind trial – the intractable migraine with aura patients with moderate or large right-to-left shunts were included (Dowson et al., 2008). Patients were randomized to receive transcatheter PFO closure with the STARFlex implant or a sham procedure. After a 6-month follow-up, there were no differences in migraine cessation rates between the two groups (primary outcome measures). However, excluding two outliers, the implant group demonstrated a greater reduction in the frequency of migraine attacks. Another study found that people who have migraine with aura are more likely to experience migraine relief following PFO closure than people who have migraine without aura (Jesurum et al., 2008). However, more puzzlingly, migraine relief can occur even if residual shunting occurs after the PFO is closed. A meta-analysis using the system Grades of Recommendation Assessment, Development and Evaluation (GRADE) by Schwedt et al. (2008) showed the evidence was low for the higher prevalence of migraine in PFO patients based on 11 observational studies, and the evidence was low to moderate for the higher prevalence of PFO in migraine patients based on seven observational studies. The efficacy of the closure of PFO in treatment of migraine was still not certain due to the major issue of the unclear definition of “improvement” in most studies (Schwedt et al., 2008).

**PSYCHIATRIC DISORDERS**

Psychiatric disorders are frequently comorbid with migraine, and result in a significant burden in patients with migraine including depression, anxiety disorder, bipolar disorder, and suicide ideation and attempt (Table 2).

**Depression**

In 1990, a Zürich prospective epidemiological cohort study on young adults aged 27 and 28 years evaluated the prevalence of psychiatric comorbidity in subjects with migraine. This study demonstrated a strong association between migraine and depression (OR = 2.2) (Merikangas et al., 1990). A bidirectional association of migraine and depression were later found in three longitudinal population-based studies (Breslau et al., 1994, 2000, 2003). In these, the risk of new onset migraine in people with depression ranged from 2.8 to 3.5. Conversely, the risk of new onset of depression in people with migraine ranged from 2.4 to 5.8. In another study, which used data from an adult US population to look at the cross-sectional associations between three pain conditions (migraine, arthritis and back pain) and three psychiatric disorders [depression, generalized anxiety disorder (GAD) and panic attacks] (McWilliams et al., 2004), the associations between the three psychiatric disorders were roughly similar. In this population, 28.5% of the migraine subjects were considered clinically depressed, while only 12.3% of subjects without migraine fit the same criteria (OR 2.8). Comorbidity with psychological distress was related to a poorer health-related quality of life in patients with migraine (Wang et al., 2001). In a recent study, patients with disabling chronic headache had high frequencies of somatic complaints (OR 8.6) and major depressive disorder (OR 25.1) (Tietjen et al., 2007). We used a 30-item version of the Chinese Health Questionnaire (CHQ-30) to screen minor psychiatric morbidity if the score was > 10 in a Taiwan population. The study showed that subjects with chronic migraine had a higher chance to have a positive screening result in the CHQ-30 score (>10) than those with chronic tension-type headache (CTTH) (66% vs. 36%) (Lu et al., 2001). In clinic-based studies, patients with chronic daily headache, especially chronic migraine, had high frequencies of major depression and panic disorders (Juang et al., 2000). In addition, the presence of major depression was a poor outcome predictor in patients with chronic daily headache (RR = 1.8) (Lu et al., 2000).

**Generalized anxiety disorder**

The association between anxiety and migraine was noted in both clinic and community-based studies (Merikangas et al., 1990; Breslau et al., 1991; Smoller et al., 2003; McWilliams et al., 2004). The study conducted by McWilliams and his colleagues also showed the association between migraine and anxiety: 9.1% of subjects with migraine have GAD, compared to 2.5% of those without migraine (OR = 3.9) (McWilliams et al., 2004). In the epidemiology cohort study in Zurich, the prevalence of GAD was high (OR = 5.3). The authors suggested that migraine with anxiety and depression may constitute a distinct syndrome comprising anxiety, often manifested in early childhood, followed by the occurrence of migraine headaches, and then by discrete episodes of depressive disorders in adulthood (Merikangas et al., 1990).

**Panic disorder**

A high frequency of panic disorders was noted in patients with migraine (Breslau et al., 1991) and vise versa (Stewart et al., 1989, 1994; Marazziti et al., 1999). A population-based study evaluated the temporal relation of migraine and panic disorder (Breslau et al., 2001). In the study, the life-time prevalence of panic disorder was not only higher in subjects with migraine, but also in those with other severe headaches (compared to controls). In addition,
the onset of panic disorder was significantly higher in subjects with migraine or severe headache (HR: 3.55 vs. 5.75, respectively). The onset of migraine or severe headache was also more frequent in subjects with panic disorder (HR: 2.10 vs. 1.85, respectively). The study indicates a higher frequency of panic disorder was not specifically in migraine patients but also in other severe headache patients. A bidirectional temporal relationship was found between headache and panic disorder with a stronger direction of headache to panic disorder (Breslau et al., 2001).

**Bipolar disorders**

The number of studies focusing on the relationship between migraine and bipolar disorders were much less than those for anxiety and depression. Most of them were clinic-based (Younes et al., 1986; Mahmood et al., 1999; Low et al., 2003). Two population-based studies reported the positive association between migraine and bipolar disorders in young adults (OR: 2.9–7.3) (Merikangas et al., 1990; Breslau et al., 1991).

**Suicide ideation and suicide attempt**

Breslau et al. (1991) and Breslau (1992) first reported that a history of migraine with aura was associated with increased frequencies of suicidal ideation and suicide attempts in young adults. One of our community-based studies in Taiwan showed young adolescents with CDH had a high frequency of psychiatric comorbidity (around 50%). In addition, 20% of adolescents with CDH had a high suicide risk (Wang et al., 2007). This association was demonstrated in subjects with migraine with aura, but not in those with migraine without aura. In our epidemiological study on young adolescents aged 13–15, migraine with aura (adjusted OR 1.79) and high headache frequency (>7 days/month) (adjusted OR 1.69) were both associated with suicidal ideation (Wang et al., 2009).

**RESTLESS LEGS SYNDROME (RLS)**

Restless legs syndrome is a common sensorimotor disorder, and has long been considered related to dopaminergic system dysfunction. A higher prevalence of RLS (17.3–34%) in patients with migraine was reported in several studies (Young et al., 2003; Rhode et al., 2007; d’Onofrio et al., 2008). Our clinic-based study, recruiting 1,041 patients with primary headache disorders, showed the frequencies of RLS were higher in patients with migraine (11.4%) than those with tension-type headache (4.6%) or cluster headache (2.0%) (Chen et al., 2010). Migraine patients who also had RLS were more likely to have photophobia, phonophobia, exacerbation due to physical activities, vertigo, dizziness, tinnitus, and neck pain. They were also more likely to report disability, depression, and poor sleep quality. The origin of the comorbidity of RLS in migraine patients remains unclear. We suggest a shared dopaminergic dysfunction in the A11 nucleus as an explanation for the association (Chen et al., 2010).

**OBESITY**

The relationship between migraine and obesity remains uncertain. In two population-based studies, BMI was not associated with the prevalence of episodic migraine (Bigal et al., 2006; Winter et al., 2009). In addition, BMI was reported to be associated with migraine frequency and chronification (Bigal et al., 2006, 2007a; Winter et al., 2009). However, two other epidemiological studies found a positive association between migraine and increased BMI (Ford et al., 2008; Peterlin et al., 2010). It is noteworthy that the two positive studies used direct measurement of BMI; whereas, the two negative studies adopted self-report BMI values.

**EPILEPSY**

The association between migraine and epilepsy is still controversial. In some studies, a higher prevalence of migraine was noted in epilepsy patients, but some studies reported differently (Marks and Ehrenberg, 1993; Lipton et al., 1994; Karali-Savrun et al., 2002; Nuyen et al., 2006). The prior studies suggest a shared genetic link between epilepsy and migraine (Baykan et al., 2004; Deprez et al., 2007; Tikka-Kleemola et al., 2010). Migraine had been reported in one family with adult onset myoclonic epilepsy (Saka and Saygi, 2000) and in one family with autosomal recessive idiopathic epilepsy (Baykan et al., 2004). A linkage analysis in a large Belgian family with occipitotemporal lobe epilepsy associated with migraine with visual aura provided evidence for a novel epilepsy and migraine susceptibility locus on chromosome 9q21–q22 (Deprez et al., 2007). A genome-wide linkage study in 36 Finnish families with at least 2 family members having scintillating scotoma revealed the same locus for visual aura (Tikka-Kleemola et al., 2010). Intriguingly, one of the genes in this region, SCH3, is highly expressed in occipital and temporal lobes, and regulates the neuronal adaptation against environmental stress (Trogrlio et al., 2004).

**CHRONIC PAIN DISORDERS**

Several chronic pain disorders were reported to be associated with migraine. The Nord-Trøndelag Health Study (Hagen et al., 2002) noted that subjects with headache reported more musculoskeletal pain than those without. The risk was similar between migraine and non-migraine headache patients (OR = 1.9 vs. 1.8). However, headache frequency was a strong predictor for musculoskeletal pain. Von Korff et al. (2005) also found that patients with self-reported chronic spine pain were associated with migraine with an OR of 5.2. Fibromyalgia was very common in patients with migraine with frequencies between 22 and 40% (Peres et al., 2001; Ifergane et al., 2006; de Tommaso et al., 2009) The development of fibromyalgia was highly associated with migraine frequency. Patients who suffered from both migraine and fibromyalgia reported a higher prevalence of insomnia, lower quality of life and more mental stress (Peres et al., 2001; de Tommaso et al., 2009). It is interesting that the fibromyalgia was more frequent in female migraine patients than male patients (Ifergane et al., 2006; de Tommaso et al., 2009).

**OTHER COMORBID DISORDERS**

Regarding asthma, one large epidemiological study (Head-Hunt study) performed in Norway reported that both migraine and non-migrainous headaches were related to asthma and chronic bronchitis (Aamodt et al., 2007). Of note, the association was more related to headache frequencies than headache diagnoses (Aamodt et al., 2007). But, in another study, the incidence of newly diagnosed asthma was not different between subjects with and without migraine (OR 1.17) (Becker et al., 2008). The association between
migraine and irritable bowel disease was also noted in some clinical and epidemiological studies (Azpiroz et al., 2000; Vandvik et al., 2004; Mulak and Paradowski, 2005; Cole et al., 2006). Based on a dataset of a national US health care plan, patients with irritable bowel syndrome had a higher OR (1.6) to have migraine, compared with those without (Cole et al., 2006). High frequency of celiac disease was also noted in migraine patients (Gabrielli et al., 2003; Alehan et al., 2008). In addition, one hospital-based study reported a high migraine frequency (12.6% vs. 5.7%) in children and young adults with celiac disease (Zelnik et al., 2004). These results support the conclusion that celiac disease was one comorbid disorder of migraine. Furthermore, chronic fatigue syndrome (Peres et al., 2002; Tietjen et al., 2010), Raynaud’s phenomenon, systemic lupus erythematosus (Mizutani et al., 1985; Terwindt et al., 1998; Glanz et al., 2001; Weder-Cisneros et al., 2004) and narcolepsy (Dahmen et al. 1999, 2003; DMKG study group, 2003) were also reported to be associated with migraine in hospital-based studies.

**DISCUSSION**

The pathophysiology of the link between migraine and comorbid disorders is uncertain. Several possibilities have been proposed.

**POSSIBLE SHARED MECHANISMS BETWEEN MIGRANE WITH AURA AND CVD**

First, subjects with migraine with aura may have other traditional cardiovascular risk factors, which increase the risk ofvascular diseases, such as higher total cholesterol, lower high-density lipoprotein cholesterol (HDL), higher total cholesterol-to-HDL ratios and higher blood pressure (Scher et al., 2005b). Second, the proinflammatory or vasoactive peptide released during migraine attacks may damage the vascular endothelium and result in stroke or other vascular events (Kurth et al., 2006; Tietjen, 2007). Third, lower levels of endothelial progenitor cells in migraineurs indicated a reduced endothelial repair capacity, particularly in migraine with aura, which may contribute to the association between migraine and vascular diseases (Elkind, 2008; Lee et al., 2008). Fourth, the genetic risk factors are possible shared mechanisms between migraine and cardiovascular diseases (Scher et al., 2006; Schürks et al., 2008). The ACE DD genotype was reported to act in combination with the MTHFR T/T genotype to increase migraine susceptibility, with the greatest effect in those with aura (Lea et al., 2005).

**POSSIBLE SHARED MECHANISMS BETWEEN MIGRANE AND PSYCHIATRIC DISORDERS**

The proposed mechanism is the shared serotonergic dysfunction between migraine and affective disorders (Hamel, 2007). Plasma level of serotonin was decreased during migraine attacks and increased during migraine attacks (Ferrari and Saxena, 1993). Second, migraine and depression were 2–3 times more common in women than in men, with a similar monthly fluctuation (Kessler et al., 1994; Lipton et al., 2001). As the ovarian hormones change, particularly the estrogen decline, they may induce down-regulation of the serotonergic system and up-regulation of the sympathetic system, and result in the co-existence of migraine and affective problems (Martin and Behbehani, 2006). Third, dysregulation of the hypothalamic pituitary adrenal (HPA) axis was noted in both depression and migraine (Peres et al., 2001; Barden, 2004). It is hypothesized that activation of the HPA axis with reduced serotonin synthesis may be the link between affective disorders, migraine and obesity (Bigal et al., 2007b).

**TREATMENT IMPLICATIONS OF COMORBIDITIES**

The comorbidities should be considered when choosing acute and prophylactic agents for migraine treatment. Since migraine with aura is a well documented risk factor for CVD, conventional cardiovascular risk factors should be strictly controlled in these patients, including blood pressure control, smoking cessation and avoidance of oral contraceptive agents (Bousser et al., 2000). In migraine patients who already have CVD, ergotamines, triptans and COX-2 inhibitors should be avoided as acute abortive treatment. In addition, tricyclic antidepressants (TCAs) should be used with caution because of the risk to cause cardiac conduction abnormality. In migraine patients with depression, TCAs and selective norepinephrine re-uptake inhibitor (SNRI) are good choices for prevention, but fluoxetine and beta-blockers should be avoided, particularly in the elderly because of the risk of exacerbation of depression. Of note, fluoxetine is widely used in Europe and Asia, but not available in the United States. In addition, neuroleptics, selective serotonin re-uptake inhibitors (SSRIs), SNRI, mirtazapine and fluoxetine should be avoided in migraine patients with RLS. If migraine patients have comorbidities like epilepsy or bipolar disorder, anticonvulsants should be considered in a preventive treatment regimen.

**FUTURE DIRECTIONS FOR RESEARCH**

Large cohort studies are still needed to delineate and confirm the relationship between migraine and its comorbid diseases. Strict criteria for the diagnoses of migraine and aura should be implemented. The frequency and associated symptoms should also be recorded in detail. The comorbidities, such as cardiovascular disease, depression or RLS, should also be diagnosed with clear definitions, and the well known risk factors for these comorbid disorders need to be controlled. Furthermore, genetic and biological researches are important to investigate the shared pathophysiological mechanisms.

**CONCLUSION**

Comorbidities may emerge from population-based studies as well as clinical series or case-control studies. Results from the latter two designs must be taken into account with caution, due to the possible introduction of Berkson’s bias or other selection bias (Bonavita and De Simone, 2008). Patients with migraine, especially migraine with aura, are at an increased risk of CVD and psychiatric disorders. Women with migraine seem to have a higher risk of CVD, compared to men. The association of migraine and depression and panic disorder is bidirectional. Young adults or adolescents with migraine with aura have a higher suicide risk. New data on comorbid RLS, epilepsy, obesity and asthma are emerging. Understanding the association of migraine with comorbid health conditions is important in providing optimal care, as well as helping understand the underlying mechanisms of migraine.

**ACKNOWLEDGMENT**

This review was supported in part by Taipei Veterans General Hospital (V99C1-063) and Ministry of Education (Aim for the Top University Plan).
Bousser, M. G., Conard, J., Kittner, S., de Lignières, B., MacGregor, E. A, Massiou, H., Silberstein, S. D., and Tzourio, C. (2000). Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia 20, 155–156.

Breslau, N. (1992). Migraine, suicidal ideation, and suicide attempts. Neurology 42, 392–395.

Breslau, N., Davis, G. C., and Andreski, P. (1991). Migraine, psychiatric disorders, and suicide attempts: an epidemiological study of young adults. Psychiatry Res 37, 11–23.

Breslau, N., Davis, G. C., Schultz, L. R., and Peterson, E. L. (1994). Migraine and major depression: A longitudinal study. Headache 34, 387–393.

Breslau, N., Lipton, R. B., Stewart, W. F., Schultz, L. R., and Welch, K. M. (2003). Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 60, 1308–1312.

Breslau, N., Schultz, L. R., Stewart, W. F., Lipton, R. B., Lucia, V. C., and Welch, K. M. A. (2000). Headache and major depression: Is the association specific to migraine? Neurology 54, 308–313.

Breslau, N., Schultz, L. R., Stewart, W. F., Lipton, R. B., and Welch, K. M. A. (2001). Headache types and panic disorder. Neurology 56, 350–354.

Buzzi, M. G., and Moskowitz, M. A. (2005). The pathophysiology of migraine: year 2005. J. Headache Pain 6, 105–111.

Carod-Artal, F. J., de la Silveira Ribeiro, L., Braga, H., Kummer, W., Mesquita, H. M., and Vargas, A. P. (2006). Prevalence of gastrointestinal symptoms in migraine patients with and without aura compared with stroke patients. A transcranial Doppler study. Cephalalgia 26, 934–939.

Chen, P. K., Fu, J. L., Chen, S. P., and Fuh, J. L. (2000). Nongastrointestinal disorders in the irritable bowel syndrome. J. Psychiatry Neurosci. 25, 185–193.

Cherubini, E., Galli, P., and Gasbarrini, A. (2003). Association between migraine and Celiac disease: results from a preliminary case-control and therapeutic study. Am. J. Gastroenterol. 98, 625–629.

Cizzari, L., Giannini, M., and Gasbarrini, G. (2000). Migraine comorbidity sample of US adults. Cephalalgia 28, 1270–1276.

Franceschi, M., Colombo, B., Rossi, P., and Canal, N. (1997). Headache in a population-based elderly cohort. An ancillary study to the Italian Longitudinal Study of Aging (ILSA). Headache 37, 79–82.
Lipton, R. B., and Silberstein, S. D. (2004). Migraine as a risk factor for subclinical brain lesions. JAMA 291, 427–434.

Kurth, T., Gazzano, J. M., Cook, N. R., Logroscino, G., Diener, H. C., and Buring, J. E. (2007). Migraine and risk of cardiovascular disease in men. Arch. Intern. Med. 167, 795–801.

Kurth, T., Gazzano, J. M., Cook, N. R., Logroscino, G., Diener, H. C., and Buring, J. E. (2006). Migraine and risk of cardiovascular disease in women. JAMA 296, 283–291.

Kurth, T., Schürks, M., Logroscino, G., Jazmín, M., and Buring, J. E. (2008). Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337, a636.

Kurth, T., Slomke, M. A., Kase, C. S., Cook, N. R., Lee, I. M., Gazzano, J. M., Diener, H. C., and Buring, J. E. (2005). Migraine, headache, and the risk of stroke in a prospective study. Neurology 65, 942–948.

Lea, R. A., Ovcaric, M., Sundholm, J., Solyom, L., Macmillan, J., and Griffis, L. R. (2005). Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. 136, 112–1177.

Lee, S. T., Chu, K., Jung, K. H., Kim, D. H., Kim, E. H., Choe, V. N., Kim, J. H., Im, W. S., Kang, L., Park, J. E., Park, H. J., Park, H. K., Song, E. C., Lee, S. K., Kim, M., and Roh, J. K. (2008). Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 70, 1510–1517.

Lipton, R. B., Ottman, R., Ehrenberg, B. L., Lee, S. T., Chu, K., Jung, K. H., Kim, D. J., and Silberstein, S. D. (2002). Fatigue in patients with migraine: association with neurologic and psychiatric conditions: results from the Zurich cohort study. J. Clin. Epidemiol. 55, 849–853.

Mazzanti, W. T., Hutchinson, M., and Oxsmorono, F. P. (1985). Association of migraine headache and Raymond’s phenomenon in systemic lupus erythematosus. Arthritis Rheum. 28, 563.

Mulak, A., and Paradowski, L. (2005). Migraine and irritable bowel syndrome. Neurol. Neurochir. Pol. 39, 555–560.

Nuyen, J., Schellevis, F. G., Satariano, W. A., Spreeuwenberg, P. M., Birkner, M. D., van der Velden, G. A., and Groenen, S. M. (2006). Comorbidity was associated with three pain conditions: results from a nationally representative sample. Pain 111, 77–83.

Merikangas, K. R., Angst, J., and Ier, H. (1990). Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch. Gen. Psychiatry 47, 849–853.

Mizutani, W. T., Hutchinson, M., and Oxsmorono, F. P. (1985). Association of migraine headache and Raymond’s phenomenon in systemic lupus erythematosus. Arthritis Rheum. 28, 563.

P. P. (2006). Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J. Clin. Epidemiol. 59, 1274–1284.

Peres, M. F., Sanchez del Rio, M., Seabra, M. L., Tuftk, S., Abucham, J., Cicapa-Neto, J., Silberstein, S. D., and Zukerman, E. (2001). Clinical data in chronic migraine associated with periventricular ARAS. Neurology 57, 2403–2408.

Peres, M. F., Young, W. B., Kaup, A. O., Zukerman, E., and Silberstein, S. D. (2001). Fibromyalgia is common in patients with transformed migraine. Neurology 57, 1326–1328.

Peres, M. F., Zukerman, E., Young, W. B., and Silberstein, S. D. (2002). Fatigue in chronic migraine patients. Cephalalgia 22, 720–724.

Peterlin, B. L., Rosso, A. L., Rapoport, A. M., and Scher, A. I. (2010). Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache 50, 52–62.

Post, M., Thijs, V., Heroelen, L., and Buds, W. (2004). Closure of patent foramen ovale is associated with decrease in prevalence of migraine. Neurology 62, 1439–1440.

Rasmussen, B. K., and Olesen, J. (1992). Symptomatic and nonsymptomatic headaches in a general population. Neurology 42, 1225–1231.

Rha, A. M., Hösing, V. G., Happe, S., Biehl, K., Young, P., and Evers, S. (2007). Comorbidity of migraine and restless legs syndrome—a case-control study. Cephalalgia 27, 1255–1260.

Rose, K. M., Carson, A. P., Sanford, C. P., Stang, P. E., Brown, C. A., Fossum, A. R., and Szolk, M. (2004). Migraine and other headaches: associations with Rose angina and coronary heart disease. Neurology 63, 2233–2239.

Rundek, T., Elkind, M. S., Di Tullio, M. R., Carrera, E., Jin, Z., Sacco, R. L., and Homma, S. (2008). Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation 118, 1419–1424.

Saka, E., and Saygi, S. (2000). Familial adult onset myoclonic epilepsy associated with migraine. Seizure 9, 344–346.

Scher, A. I., Bigal, M. E., and Lipton, R. B. (2005a). Comorbidity of migraine. Curr. Opin. Neurol. 18, 305–310.

Scher, A. I., Terwindt, G. M., Picavet, H. S., Verschuren, W. M., Ferrari, M. D., and Launer, L. J. (2005b). Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64, 614–620.

Scher, A. I., Gudmundsson, L. S., Sigurdsson, S., Ghambaryan, A., Asplund, T., Eiriksdottir, G., van Buchem, M. A., Gudnason, V., and Launer, L. J. (2009). Migraine headache in middle age and late-life brain infarcts. JAMA 301, 2563–2570.

Scher, A. I., Terwindt, G. M., Verschuren, W. M., Kruijt, M. C., Bloh, J. H., Kowa, H., Frants, R. R., van den Maagdenberg, A. M., van Buchem, M., Ferrari, M. D., and Launer, L. J. (2006). Migraine and MTHFR C677T genotype in a population-based sample. Am. J. Hum. Genet. 372–375.

Schürks, M., Zee, R. Y., Buring, J. E., and Kurth, T. (2008). Interrelationships among the MTHFR C677T genotype in a population-based sample. Am. J. Hum. Genet. 372–375.

Schürks, M., Zee, R. Y., Buring, J. E., and Kurth, T. (2009). ACE D/I polymorphism, migraine, and cardiovascular disease. Neurology 71, 505–513.

Schürks, M., Zee, R. Y., Buring, J. E., and Kurth, T. (2009). ACE D/I polymorphism, migraine, and cardiovascular disease. Neurology 71, 505–513.

Tietjen, E. G. (2007). Migraine and ischemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia 27, 981–987.

Tietjen, E. G., Brandes, J. L., Digs, K. B., Barger, S., Martin, V., Recobor, A., Geweke, L., Hafez, E., Aurora, S. K., Herial, N. A., Utley, C., and Khuder, S. A. (2007). High prevalence of somatic symptoms and depression in women
with disabling chronic headache. Neurology 68, 134–140.

Tietjen, G. E., Brandes, J. L., Peterlin, B. L., Eloff, A., Dafer, R. M., Stein, M. R., Drexler, E., Martin, V. T., Hutchinson, S., Aurora, S. K., Recober, A., Herial, N. A., Utley, C., White, L., and Khuder, S. A. (2010). Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. Headache 50, 42–51.

Tikka-Kleemola, P., Artto, V., Vepsäläinen, S., Sobel, E. M., Räty, S., Kaunisto, M. A., Anttila, V., Hamalainen, E., Sumelahit, M. L., Ilmavirta, M., Färkkilä, M., Kallela, M., Palotie, A., and Wessman, M. (2010). A visual migraine aura locus maps to 9q21–q22. Neurology 74, 1171–1177.

Troglio, F., Echart, C., Gobbi, A., Pawson, T., Pelicci, P. G., De Simoni, M. G., and Pelicci, G. (2004). The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 101, 15476–15481.

Tzourio, C., Gagnière, B., El Amrani, M., Alpérovitch, A., and Bousser, M. G. (2003). Relationship between migraine, blood pressure and carotid thickness. A population-based study in the elderly. Cephalalgia 23, 914–920.

Vanvik, P. O., Wilhelmsen, I., Ihlebaek, C., and Furup, P. G. (2004). Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment. Pharmacol. Ther. 20, 1195–1203.

Von Korff, M., Crane, P., Lane, M., Miglioretti, D. L., Simon, G., Saunders, K., Stang, P., Brandenburg, N., and Kessler, R. (2005). Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. Pain 113, 331–339.

Wang, S. J., Fuh, J. L., Jiang, K. D., and Lu, S. R. (2007). Psychiatric comorbidity and suicide risk in adolescents with chronic daily headache. Neurology 68, 1468–1473.

Winter, A. C., Berger, K., Buring, J. E., and Kurth, T. (2009). Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia 29, 269–278.

Young, W. B., Piovesan, E. J., and Biglan, K. M. (2003). Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr. 8, 450–456.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 05 March 2010; paper pending published: 29 April 2010; accepted: 28 June 2010; published online: 23 August 2010.

Citation: Wang S-J, Chen P-K and Fuh J-L (2010) Comorbidities of migraine. Front. Neurol. 1:16. doi: 10.3389/fneur.2010.00016

This article was submitted to Frontiers in Headache Medicine and Facial Pain, a specialty of Frontiers in Neurology.

Copyright © 2010 Wang, Chen and Fuh. This is an open-access article subject to an exclusive license agreement between the authors and the Frontiers Research Foundation, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.